Galantos Pharma (Germany) a clinical-stage biopharmaceutical company focused on acetylcholinesterase modulation for the treatment of Alzheimer’s disease, closed a $5.7M Series C financing. Participants include VRP Rhineland Palatinate Fund, KfW Bankengruppe, F.I.B. Frankfurter Investmentbank, WFT Ventures and High-Tech Gründerfonds.